Assess whether a CMC change is a comparability or a new product (5e680a)

Situation

The desk packet is biosimilar analytical similarity report after a boxed-warning proposal from the review division. CMC change-control owner in a safety team sitting on a new disproportionate signal has to name A CMC change is a comparability or A new product for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using biosimilar analytical similarity report after a boxed-warning proposal from the review division.

Hypotheses to test

• Biosimilar analytical similarity report reads as A CMC change is a comparability once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to A new product after a boxed-warning proposal from the review division; A CMC change is a comparability would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in biosimilar analytical similarity report for CMC change-control owner in a safety team sitting on a new disproportionate signal.
• Biosimilar analytical similarity report is missing the fact CMC change-control owner needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a boxed-warning proposal from the review division and write the one fact that would move a CMC change is for CMC change-control owner.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a boxed-warning proposal from the review division). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If biosimilar analytical similarity report after a boxed-warning proposal from the review division cannot support A CMC change is a comparability versus A new product on this Pharma & Life Sciences Clinical and Evidence Strategy close, CMC change-control owner must state the unresolved clinical or safety evidence requirement explicitly.